BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27586449)

  • 1. Recent Updates on the Management of Medullary Thyroid Carcinoma.
    Kim BH; Kim IJ
    Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
    Dabelić N; Jukić T; Fröbe A
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
    Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
    Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs for medullary thyroid cancer: new promises?
    Spitzweg C; Morris JC; Bible KC
    Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fundamentals and Recent Advances in the Evaluation and Management of Medullary Thyroid Carcinoma.
    Gigliotti BJ; Brooks JA; Wirth LJ
    Mol Cell Endocrinol; 2024 Jun; ():112295. PubMed ID: 38871174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment and management approaches for medullary thyroid cancer.
    Ernani V; Kumar M; Chen AY; Owonikoko TK
    Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.
    Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD
    Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric Medullary Thyroid Carcinoma.
    Starenki D; Park JI
    J Pediatr Oncol; 2015; 3(2):29-37. PubMed ID: 27014708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical aspects and controversies in the management of medullary thyroid cancer.
    Green K; Hintze J; O'Neill JP
    Ir J Med Sci; 2022 Dec; 191(6):2461-2466. PubMed ID: 35064534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Precision medicine in endocrinology exemplified by medullary thyroid cancer].
    Brandenburg T; Machlah YM; Führer D
    Inn Med (Heidelb); 2024 Mar; 65(3):202-210. PubMed ID: 38231404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
    Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
    Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
    J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
    Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
    Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
    Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
    Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
    [No Abstract]   [Full Text] [Related]  

  • 18. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
    Saltiki K; Simeakis G; Karapanou O; Alevizaki M
    Eur J Endocrinol; 2022 Sep; 187(3):R53-R63. PubMed ID: 35895692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Guidelines for Management of Medullary Thyroid Carcinoma.
    Kim M; Kim BH
    Endocrinol Metab (Seoul); 2021 Jun; 36(3):514-524. PubMed ID: 34154310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
    Maciel LMZ; Magalhães PKR
    Arch Endocrinol Metab; 2017; 61(4):398-402. PubMed ID: 28658345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.